ArticleThe Journal of surgical research2017
Inhibition of microRNA-24 increases liver fibrosis by enhanced menin expression in Mdr2
Article in The Journal of surgical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- RUNX1-mediated repression of miR-24 promotes hepatic stellate cell activation and liver fibrosis by targeting the ALK4/Smad3 signaling pathway.Frontiers in genetics · 2026Article
- Dichotomous Roles ofInternational journal of molecular sciences · 2022Article
- The miR-23-27-24 cluster: an emerging target in NAFLD pathogenesis.Acta pharmacologica Sinica · 2022Review
- lncRNA NONRATT013819.2 promotes transforming growth factor-β1-induced myofibroblastic transition of hepatic stellate cells by miR24-3p/Open medicine (Warsaw, Poland) · 2022Article
- Gene Set Enrichment Analysis Detected Immune Cell-Related Pathways Associated with Primary Sclerosing Cholangitis.BioMed research international · 2022Article
- Versatile role of miR-24/24-1*/24-2* expression in cancer and other human diseases.American journal of translational research · 2022Review
- Diagnosis and Therapeutic Management of Liver Fibrosis by MicroRNA.International journal of molecular sciences · 2021Review
- Role of miR-24 in Multiple Endocrine Neoplasia Type 1: A Potential Target for Molecular Therapy.International journal of molecular sciences · 2021Review
- Amelioration of Large Bile Duct Damage by Histamine-2 Receptor Vivo-Morpholino Treatment.The American journal of pathology · 2020Article
- Pathobiology of biliary epithelia.Biochimica et biophysica acta. Molecular basis of disease · 2018Review
- Amelioration of hepatic steatosis is associated with modulation of gut microbiota and suppression of hepatic miR-34a inNutrition & metabolism · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundLiver transplantation remains the primary treatment for primary sclerosing cholangitis (PSC). Mdr2 MATERIALS AND
methodsMenin expression was measured in human PSC and Mdr2
resultsMenin gene expression was increased in Mdr2
conclusionsInhibition of miR-24 increases menin and TGF-β1 expression, subsequently increasing hepatic fibrosis in FVB/NJ WT and Mdr2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.